Ceftaroline fosamil is a water-soluble prodrug of the bioactive ceftaroline with the broad-spectrum antibacterial activity [1]. The bactericidal action of Ceftaroline fosamil is mediated through binding to PBPs on bacterial cell walls, leading to irreversible inhibition of cell-wall synthesis[2]. Ceftaroline fosamil has been widely used to kill drug-resistant Gram-positive and Gram-negative bacteria, as well as to treat experimental bacteraemia in animal models[3].
In vitro, Ceftaroline fosamil treatment for 24 hours significantly inhibited SARS-CoV-2 replication in Calu-3 cells with an EC50 value of 1.25µM[4].
In vivo, Ceftaroline fosamil treatment via intramuscular injection at a dose of 60mg/kg/day for 7 days significantly reduced the density of methicillin-resistant Staphylococcus aureus (MRSA) in the rabbit prosthetic joint infection model[5]. Ceftaroline fosamil (40mg/kg) administered intramuscularly every 8 hours for 3 days reduced the activity of MRSA in a rat model of endocarditis[6]. In a rabbit model of acute MRSA-infected osteomyelitis, treatment with Ceftaroline fosamil (10mg/kg) twice intravenously for 4 days significantly reduced bacterial density in synovial fluid, bone marrow, and bone[7].
References:
[1] Ye L, Zhang J, Xiao W, et al. Efficacy and mechanism of actions of natural antimicrobial drugs[J]. Pharmacology & Therapeutics, 2020, 216: 107671.
[2] Poon H, Chang M H, Fung H B. Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus[J]. Clinical therapeutics, 2012, 34(4): 743-765.
[3] García P, Moscoso M, Fernández M C, et al. Comparison of the in vivo efficacy of ceftaroline fosamil, vancomycin and daptomycin in a murine model of methicillin-resistant Staphylococcus aureus bacteraemia[J]. International Journal of Antimicrobial Agents, 2023, 62(1): 106836.
[4] Delgado C, Nogara P A, Miranda M D, et al. In Silico and In Vitro Studies of the Approved Antibiotic Ceftaroline Fosamil and Its Metabolites as Inhibitors of SARS-CoV-2 Replication[J]. Viruses, 2025, 17(4): 491.
[5] Gatin L, Saleh-Mghir A, Tasse J, et al. Ceftaroline-Fosamil efficacy against methicillin-resistant Staphylococcus aureus in a rabbit prosthetic joint infection model[J]. Antimicrobial agents and chemotherapy, 2014, 58(11): 6496-6500.
[6] Singh K V, Tran T T, Nannini E C, et al. Efficacy of ceftaroline against methicillin-susceptible Staphylococcus aureus exhibiting the cefazolin high-inoculum effect in a rat model of endocarditis[J]. Antimicrobial Agents and Chemotherapy, 2017, 61(7): 10.1128/aac. 00324-17.
[7] Jacqueline C, Amador G, Caillon J, et al. Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis[J]. Journal of antimicrobial chemotherapy, 2010, 65(8): 1749-1752.
Ceftaroline fosamil是具有生物活性的ceftaroline的水溶性前体药,具有广谱抗菌活性[1]。Ceftaroline fosamil的杀菌作用是通过与细菌细胞壁上的PBPs结合,从而不可逆地抑制细胞壁合成[2]。Ceftaroline fosamil已被广泛用于杀灭耐药革兰氏阳性和革兰氏阴性细菌,并在动物模型中用于治疗实验性菌血症[3]。
在体外,用Ceftaroline fosamil处理Calu-3细胞24小时可显著抑制SARS-CoV-2病毒复制,EC50值为1.25µM[4]。
在体内,以60mg/kg/day的剂量肌肉注射Ceftaroline fosamil治疗7天,可显著降低兔人工关节感染模型中methicillin-resistant Staphylococcus aureus (MRSA)的密度[5]。在大鼠心内膜炎模型中,以40mg/kg的剂量每8小时肌肉注射一次Ceftaroline fosamil,治疗3天,可降低MRSA的活性[6]。在兔急性MRSA感染性骨髓炎模型中,以10mg/kg的剂量静脉注射Ceftaroline fosamil,每日两次,治疗4天,可显著降低滑液、骨髓和骨骼中的细菌密度[7]。
















